期刊文献+

膀胱肿瘤术后吡柔比星灌注对患者部分血清肿瘤标记分子及增殖和侵袭分子mRNA的影响 被引量:2

Effect of Pirubicin Intravesical Infusion on Serum Tumor Markers and mRNA Contents of Proliferation and Invasion Molecules in Bladder Tumor Patients
下载PDF
导出
摘要 目的:探讨吡柔比星膀胱灌注化疗对膀胱肿瘤术后患者部分血清肿瘤标记分子及增殖和侵袭分子mRNA含量的影响。方法:206例行经尿道膀胱肿瘤电切术治疗膀胱肿瘤患者均分为观察组与对照组,对照组术后采用常规治疗,观察组术后采用吡柔比星膀胱灌注规范化疗1年,对两组患者定期随访1年;治疗前和治疗结束时,分别测定2组患者血清分泌型蛋白(DKK)、血管内皮生长因子(VEGF)、成纤维细胞生长因子(FGF)、基质金属蛋白酶-2(MMP-2)及MMP-9水平,检测血清组蛋白-赖氨酸N-甲基转移酶(EZH2)、细胞周期素(Cyclin D1)、外泌体(exosomes)及可溶性血管黏附分子(s VCAM)mRNA含量,比较2组患者随访期间肿瘤复发率及并发症。结果:与治疗前相比,治疗结束时2组患者血清DKK、VEGF、FGF、MMP-2及MMP-9水平均显著下降,观察组下降更显著(P<0.01);2组患者血清EZH2、Cyclin D1、exosomes及s VCAM mRNA含量也均显著下降(P<0.01),且观察组下降也更显著(P<0.05或P<0.01);随访期间观察组肿瘤复发率显著低于对照组(P<0.01),但2组发症总发生率比较差异无统计学意义(P>0.05)。结论:膀胱肿瘤术后行吡柔比星膀胱灌注化疗可降低患者血清肿瘤标记分子水平及增殖和侵袭分子mRNA含量,且术后复发率低。 Objective: To investigate the effect of pirubicin intravesical infusion chemotherapy on serum tumor markers and mRNA contents of proliferation and invasion molecules in bladder tumor patients after operation. Methods: Two hundred and six cases of bladder tumor patients that received transurethral bladder tumor electrocision in our hospital were selected and randomly divided into observation group( group OB) and control group( group CN) with 103 cases in each group. Patients in group CN were treated with routine postoperative treatment,while those in group OB were given pirubicin intravesical infusion chemotherapy for 1 continuous year after the operation. Following-up observation was made on the 2 groups for 1 year. The serum tumor marker molecular level and molecular mRNA contents of proliferation and invasion molecules of the 2 groups were tested before and after the treatment and compared; The rates of recurrence and incidence of complications during the following-up period of2 groups were statistically analyzed. Results: The serum tumor marker molecular levels of DKK,VEGF,FGF,MMP-2 and MMP-9 of the 2 groups significantly decreased after treatment than before,and those in group OB were even obviously lower than in group CO( P 〈0. 01); The mRNA contents of proliferation and invasion molecular such as EZH2,Cyclin D1,exosomes and s VCAM of the 2 groups after treatment significantly decreased than before( P 〈0. 01),and those in group OB were even obviously lower than in group CO( P 〈0. 05 or P〈 0. 01); The recurrence rate of group OB was significantly lower than that of group CN during the following-up period( P 〈0. 01),while the total incidence of complications of the 2 groups did not differ significantly( P〉 0. 05). Conclusion: Intravesical instillation of pirarubicin after bladder tumor surgery can decrease serum tumor marker molecular levels and mRNA contents of proliferation and invasion molecular,and reduce postoperative recurrence rate.
作者 薛玉泉 王振龙 张亚萍 种铁 XUE Yuquan, WANG Zhenlong, ZHANG Yaping, CHONG Tie(Department of Urinary Surgery, the Second Affiliated Hospital of Xi~m Jiaotong University, Xi'an 710000, Shaanxi, Chin)
出处 《贵州医科大学学报》 CAS 2018年第3期310-313,319,共5页 Journal of Guizhou Medical University
基金 国家自然科学基金(81000293)
关键词 膀胱肿瘤 肿瘤复发 局部 吡柔比星 膀胱灌注化疗 肿瘤标记分子 增殖和侵袭分子 bladder tumor tumor recurrence, part pirubicin intravesical infusion chemotherapy tumor marker molecular proliferation and invasion molecules
  • 相关文献

二级参考文献42

  • 1李宁忱,肖云翔,宋毅,张凯,袁建峰,龚侃,那彦群.132例膀胱内灌注吡柔比星预防浅表性膀胱癌术后复发[J].中国肿瘤临床,2005,32(21):1245-1247. 被引量:8
  • 2田溪泉,邢念增,王勇,李建兴.早期吡柔比星膀胱内灌注预防膀胱癌术后复发[J].临床泌尿外科杂志,2006,21(1):4-6. 被引量:35
  • 3Pacheco-Figueiredo L,Antunes L,Bento MJ,et al.Evaluation of the frequency of and survival from second primary cancers in North Portugal:apopulation-based study[J].Eur J Cancer Prev,2013,22(6):599-606.
  • 4Allchorne P,Lamb BW,Kinsella J,et al.Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure[J].Urol Nurs,2014,34(2):95-99.
  • 5Milla P,Fiorito C,Soria F,et al.Intravesical thermo-chemotherapy based on conductive heat:a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients[J].Cancer Chemother Pharmacol,2014,73(3):503-509.
  • 6Hirata T,Watanabe M,Kaku H,et al.REIC/Dkk-3-encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer[J].Int J Oncol,2012,41(2):559-564.
  • 7Kaba M,Pirincci N,Benli E,et al.Dickkopf-1levels in Turkish patients with bladder cancer and its association with clinicopathological features[J].Asian Pac J Cancer Prev,2014,15(1):381-384.
  • 8Pili R,Qin R,Flynn PJ,et al.A phaseⅡsafety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer[J].Clin Genitourin Cancer,2013,11(4):477-483.
  • 9Laurent VM,Duperray A,Sundar Rajan V,et al.Atomic force microscopy reveals a role for endothelial cell icam-1expression in bladder cancer cell adherence[J].PLoS One,2014,9 (5):e98034.
  • 10Wieczorek E,Reszka E,Jablonowski Z,et al.Genetic polymorphisms in matrix metalloproteinases(MMPs)and tissue inhibitors of MPs(TIMPs),and bladder cancer susceptibility[J].BJU Int,2013,112(8):1207-1214.

共引文献55

同被引文献22

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部